Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyllis J Goodman

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Controlled Clinical Trials|March 17, 2004
Implementation of the Prostate Cancer Prevention Trial (PCPT)Phyllis J Goodman, Catherine M Tangen, John J Crowley, et al.
JAMA|July 7, 2005
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Endocrine-Related Cancer|December 10, 2021
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trialCindy H Chau, Cathee Till, Douglas K Price, et al.
The New England Journal of Medicine|August 16, 2013
Long-term survival of participants in the prostate cancer prevention trialIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Nutrients|April 19, 2017
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention TrialFayth L Miles, Phyllis J Goodman, Catherine Tangen, et al.
The Prostate|July 12, 2008
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trialMarian L Neuhouser, Jeannette Schenk, Yoon Ju Song, et al.
Journal of the National Cancer Institute|April 20, 2006
Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 3, 2014
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention TrialJeannette M Schenk, Cathee A Till, Catherine M Tangen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Controlled Clinical Trials|March 17, 2004
Implementation of the Prostate Cancer Prevention Trial (PCPT)Phyllis J Goodman, Catherine M Tangen, John J Crowley, et al.
JAMA|July 7, 2005
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Endocrine-Related Cancer|December 10, 2021
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trialCindy H Chau, Cathee Till, Douglas K Price, et al.
The New England Journal of Medicine|August 16, 2013
Long-term survival of participants in the prostate cancer prevention trialIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Nutrients|April 19, 2017
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention TrialFayth L Miles, Phyllis J Goodman, Catherine Tangen, et al.
The Prostate|July 12, 2008
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trialMarian L Neuhouser, Jeannette Schenk, Yoon Ju Song, et al.
Journal of the National Cancer Institute|April 20, 2006
Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 3, 2014
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention TrialJeannette M Schenk, Cathee A Till, Catherine M Tangen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
Pageof 16